{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:11:49Z","timestamp":1761883909390,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.reumae.2020.10.006","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T11:53:10Z","timestamp":1646740390000},"page":"150-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study"],"prefix":"10.1016","volume":"18","author":[{"given":"Jos\u00e9","family":"Rosas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Pasquau","family":"Lia\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica Llombart","family":"Cant\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda Carrasco","family":"Barea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo Raga","family":"Beser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Tom\u00e1s Algado","family":"Rabasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Mart\u00ednez","family":"Adsuar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian Vila","family":"Auli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel Fern\u00e1ndez","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda Garijo","family":"Sainz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere Esquerdo","family":"Ramis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Ruiz","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aa Luisa Navarrete","family":"Rebollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel Hern\u00e1ndez","family":"Lorido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura G\u00f3mez","family":"Escolar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2020.10.006_bib0160","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2020.10.006_bib0165","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/22221751.2020.1746199","article-title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia","volume":"9","author":"Lin","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.reumae.2020.10.006_bib0170","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"Li","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.reumae.2020.10.006_bib0175","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.reumae.2020.10.006_bib0180","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.reumae.2020.10.006_bib0185","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1148\/radiol.2020200274","article-title":"Emerging 2019 novel coronavirus (2019-nCoV) pneumonia","volume":"295","author":"Song","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.reumae.2020.10.006_bib0190","doi-asserted-by":"crossref","first-page":"m1091","DOI":"10.1136\/bmj.m1091","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study","volume":"368","author":"Chen","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.reumae.2020.10.006_bib0195","doi-asserted-by":"crossref","first-page":"337","DOI":"10.55563\/clinexprheumatol\/xcdary","article-title":"COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?","volume":"38","author":"Sarzi-Puttini","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2020.10.006_bib0200","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.reumae.2020.10.006_bib0205","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0140-6736(20)30567-5","article-title":"How will country-based mitigation measures influence the course of the COVID-19 epidemic?","volume":"395","author":"Anderson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2020.10.006_bib0210","unstructured":"Red Nacional de Vigilancia Epidemiol\u00f3gica. Situaci\u00f3n de COVID-19 en Espa\u00f1a. Informe 22 [Internet]. 2020. Available from: https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Documents\/INFORMES\/Informes%20COVID-19\/Informe%20n%C2%BA%2022.%20Situaci%C3%B3n%20de%20COVID-19%20en%20Espa%C3%B1a%20a%2013%20de%20abril%20de%202020.pdf."},{"key":"10.1016\/j.reumae.2020.10.006_bib0215","article-title":"Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020","volume":"25","author":"Wu","year":"2020","journal-title":"Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull"},{"key":"10.1016\/j.reumae.2020.10.006_bib0220","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2020.10.006_bib0225","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2020.10.006_bib0230","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.reumae.2020.10.006_bib0235","doi-asserted-by":"crossref","first-page":"m1432","DOI":"10.1136\/bmj.m1432","article-title":"Chloroquine and hydroxychloroquine in covid-19","volume":"369","author":"Ferner","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.reumae.2020.10.006_bib0240","unstructured":"Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv: 202003.00026v1. [Epub ahead of print]."},{"key":"10.1016\/j.reumae.2020.10.006_bib0245","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2020.20203","article-title":"2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate: a word of caution","volume":"150","author":"Battegay","year":"2020","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.reumae.2020.10.006_bib0250","unstructured":"European Centre for Disease Prevention and Control. Coronavirus disease 2019 (COVID-19) in the EU\/EEA and the UK \u2013 eighth update 2020. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/rapid-risk-assessment-coronavirus-disease-2019-covid-19-pandemic-eighth-update."},{"key":"10.1016\/j.reumae.2020.10.006_bib0255","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.10.006_bib0260","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2020.10.006_bib0265","first-page":"694","article-title":"The effect of JAK1\/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib","volume":"37","author":"Choy","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2020.10.006_bib0270","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.reumae.2020.10.006_bib0275","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2020.10.006_bib0280","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments [published online ahead of print, 2020 Feb 27]","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.reumae.2020.10.006_bib0285","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1164\/ajrccm.149.3.7509706","article-title":"The American European Consensus Conference on ARDS, definitions, mechanisms, relevant outcomes, and clinical trial coordination","volume":"149","author":"Bernard","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.reumae.2020.10.006_bib0290","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2020.10.006_bib0295","article-title":"Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients","author":"Chen","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.reumae.2020.10.006_bib0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.rce.2020.07.003","article-title":"Caracter\u00edsticas cl\u00ednicas de los pacientes hospitalizados con COVID-19 en Espa\u00f1a: resultados del Registro SEMI-COVID-19","author":"Casas-Rojo","year":"2020","journal-title":"Revista Cl\u00ednica Espa\u00f1ola"},{"key":"10.1016\/j.reumae.2020.10.006_bib0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.04.017","article-title":"Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact","author":"Cantini","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.reumae.2020.10.006_bib0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.06.052","article-title":"Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia","author":"Cantini","year":"2020","journal-title":"J Infect"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S217357432200034X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S217357432200034X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:01:01Z","timestamp":1761879661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S217357432200034X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S217357432200034X"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2020.10.006","relation":{},"ISSN":["2173-5743"],"issn-type":[{"type":"print","value":"2173-5743"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2020.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}